In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Eurogene and Valentis announce collaboration
Crucell signs licensing deal with Eurogene
Juvaris BioTherpeutics Expands Relationship With Valentis
Endovasc to begin human heart trials of nicotine-based blood vessel growth agent
Valentis initiates gene therapy clinical trial
Valentis enters cross license agreement with Genzyme
Valentis Expands License Agreement With Genzyme Corporation
Valentis licenses GeneSwitch technology to Lexicon
Urigen N.A., Inc. Completes Reverse Merger With Valentis, Inc.